– USA, MD – NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced the appointment of Dr. Leena Gandhi (M.D., Ph.D.) to its Board as a Non-Executive Director.
“Leena is an excellent addition to the NexImmune Board. She brings substantial translational and early clinical and immuno-oncology experience to our organization. Her expertise in developing and conducting innovative clinical trials across multiple malignancies will be extremely valuable as we advance the clinical development of our current and future therapies. On behalf of the Company and the entire Board, I would like to welcome Leena to the team” said Board Chairman, Sol Barer.
About Dr. Leena Gandhi
Dr. Leena Gandhi is the Director of the Center for Cancer Therapeutic Innovation, a cross-malignancy novel therapeutics hub, at the Dana-Farber Cancer Institute. Dr. Gandhi was on staff at DFCI for 8 years as a thoracic oncologist working in early drug development before moving to New York University to serve as the Director of Thoracic Medical Oncology. She has focused her research on novel drug development and biomarkers for selection in lung cancer with a particular focus on immuno-oncology. She led pivotal studies demonstrating the utility of PDL1 as a biomarker for the efficacy of anti-PD1 agents in lung cancer and studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. She served as VP of Immuno-Oncology Development at Eli Lilly leading the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020.
“I am honored to join the board of NexImmune at this pivotal juncture in the Company’s work,” said Dr. Leena Gandhi. “I am excited to work with NexImmune’s leadership on maximizing the potential of its novel technology in multiple different clinical applications using not only adoptive cell therapy but also a versatile injectable platform. This unique approach has tremendous opportunity to modulate immune responses in cancer and other areas.”
She received her Ph.D. from the University of California, Berkeley in 1998 and her M.D. from New York University in 2002. She completed her postgraduate training at Massachusetts General Hospital and Dana-Farber Cancer Institute in Boston.
About NexImmune
NexImmune is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s T cells to generate a specific, potent, and durable immune response. The backbone of NexImmune’s approach is a proprietary Artificial Immune Modulation nanoparticle technology platform. The AIM technology enables NexImmune to construct nanoparticles that function as synthetic dendritic cells capable of directing a specific T cell-mediated immune response. AIM constructed nanoparticles employ natural biology to engage, activate and expand endogenous T cells in ways that combine anti-tumor attributes of antigen-specific precision, potency, and long-term persistence with reduced potential for off-target toxicities.
NexImmune’s two lead programs, NEXI-001 and NEXI-002, are in Phase 1/2 clinical trials for the treatment of relapsed AML after allogeneic stem cell transplantation and multiple myeloma refractory to at least three prior lines of therapy, respectively. NexImmune is also developing new AIM nanoparticle constructs and modalities for potential clinical evaluation in oncology and disease areas outside of oncology, including autoimmune disorders and infectious diseases.
For more information: https://www.neximmune.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
